The stock has a 36-month beta value of 1.39. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GDRX is 77.45M, and at present, short sellers hold a 11.36% of that float. On May 08, 2024, the average trading volume of GDRX was 1.30M shares.
GDRX) stock’s latest price update
The stock of GoodRx Holdings Inc (NASDAQ: GDRX) has increased by 0.80 when compared to last closing price of 7.47. Despite this, the company has experienced a 6.06% gain in its stock price over the last five trading sessions. MarketBeat reported 2024-04-22 that The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.
GDRX’s Market Performance
GDRX’s stock has risen by 6.06% in the past week, with a monthly rise of 10.09% and a quarterly rise of 24.05%. The volatility ratio for the week is 4.18% while the volatility levels for the last 30 days are 4.16% for GoodRx Holdings Inc The simple moving average for the past 20 days is 9.02% for GDRX’s stock, with a 18.18% simple moving average for the past 200 days.
Analysts’ Opinion of GDRX
Many brokerage firms have already submitted their reports for GDRX stocks, with KeyBanc Capital Markets repeating the rating for GDRX by listing it as a “Overweight.” The predicted price for GDRX in the upcoming period, according to KeyBanc Capital Markets is $9 based on the research report published on April 10, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see GDRX reach a price target of $10, previously predicting the price at $7.50. The rating they have provided for GDRX stocks is “Overweight” according to the report published on March 25th, 2024.
JP Morgan gave a rating of “Overweight” to GDRX, setting the target price at $10 in the report published on March 01st of the current year.
GDRX Trading at 7.57% from the 50-Day Moving Average
After a stumble in the market that brought GDRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.64% of loss for the given period.
Volatility was left at 4.16%, however, over the last 30 days, the volatility rate increased by 4.18%, as shares surge +11.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.14% upper at present.
During the last 5 trading sessions, GDRX rose by +6.06%, which changed the moving average for the period of 200-days by +8.66% in comparison to the 20-day moving average, which settled at $6.95. In addition, GoodRx Holdings Inc saw 12.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GDRX starting from Wagner Scott, who purchase 21,652 shares at the price of $5.76 back on Nov 30 ’23. After this action, Wagner Scott now owns 182,900 shares of GoodRx Holdings Inc, valued at $124,806 using the latest closing price.
Wagner Scott, the of GoodRx Holdings Inc, purchase 26,348 shares at $5.90 during a trade that took place back on Nov 29 ’23, which means that Wagner Scott is holding 161,248 shares at $155,482 based on the most recent closing price.
Stock Fundamentals for GDRX
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.85 for the gross margin
The net margin for GoodRx Holdings Inc stands at -0.01. The total capital return value is set at -0.01. Equity return is now at value -1.12, with -0.55 for asset returns.
Based on GoodRx Holdings Inc (GDRX), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 0.87. The interest coverage ratio of the stock is -0.33.
Currently, EBITDA for the company is 163.15 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 4.02. The receivables turnover for the company is 4.69for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.12.
Conclusion
To sum up, GoodRx Holdings Inc (GDRX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
